Antithymocyte globulin therapy for pure white cell aplasia.
Severe neutropenia due to selective loss from the bone marrow of cells of the entire neutrophil maturation sequence developed in a patient with Goodpasture's Syndrome and was associated with serious infections complicating continuous ambulatory peritoneal dialysis. Involvement of T-lymphocytes in the process affecting the neutrophil series was implicated by the relation between recovery from neutropenia and treatment with antithymocyte globulin (ATG). Azathioprine and corticosteroid administration failed to sustain recovery from neutropenia induced by ATG. It is concluded that ATG can provide a nonmyelotoxic form of therapy for pure white cell aplasia whose effectiveness is independent of responsiveness to other immunosuppressive agents.
D000328:Adult; D000380:Agranulocytosis / Q000188:drug therapy*; D000906:Antibodies / Q000032:analysis; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001854:Bone Marrow Cells; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D000906:Antibodies; D000961:Antilymphocyte Serum